Related Experiment Video

Updated: Jul 11, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

BCL-2 family regulation by the 20S proteasome inhibitor bortezomib

D A Fennell1, A Chacko, L Mutti

  • 1Thoracic Oncology Research Group, Centre for Cancer Research and Cell Biology, Queen's University Belfast, Northern Ireland, UK. d.fennell@qub.ac.uk

Oncogene
|September 11, 2007
PubMed

Insights

Bortezomib, a proteasome inhibitor, triggers cancer cell death by stabilizing BH3-only proteins. This mechanism is crucial for BAX- and BAK-dependent apoptosis, suggesting new therapeutic strategies.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Bortezomib is a proteasome inhibitor approved for multiple myeloma and investigated in solid tumors.
  • Its complex mechanisms of cancer cell toxicity are under active research.
  • Evidence points to the BCL-2 family as a key target of proteasome inhibition.

Purpose of the Study:

  • To review the mechanisms of bortezomib-induced cancer cell death.
  • To highlight the role of proteasome inhibition in regulating the BCL-2 family.
  • To explore implications for novel drug interactions.

Main Methods:

  • Literature review of studies on bortezomib and cancer cell death pathways.
  • Analysis of proteasome inhibition-dependent regulation of BCL-2 family proteins.
  • Examination of BH3-only protein stabilization and its downstream effects.

Main Results:

  • Proteasome inhibition by bortezomib leads to the stabilization of BH3-only proteins, including BIK, NOXA, and BIM.
  • Stabilized BH3-only proteins are essential for initiating BAX- and BAK-dependent apoptosis.
  • These findings underscore a critical pathway for bortezomib's cytotoxic effects.

Conclusions:

  • Proteasome inhibition-dependent regulation of the BCL-2 family is a key mechanism of bortezomib's anti-cancer activity.
  • The stabilization of specific BH3-only proteins is vital for inducing cell death.
  • Understanding these pathways opens avenues for developing synergistic drug combinations.

More Related Videos

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons09:27

Cell Subtype-specific Analysis of Neuronal Membrane Proteasome in Somatosensory Neurons

Published on: October 10, 2025

Examining BCL-2 Family Function with Large Unilamellar Vesicles08:35

Examining BCL-2 Family Function with Large Unilamellar Vesicles

Published on: October 5, 2012

Related Concept Videos

The Intrinsic Apoptotic Pathway01:31

The Intrinsic Apoptotic Pathway

Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The Proteasome01:13

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3 (ubiquitin...
The Proteasome02:18

The Proteasome

Eukaryotic cells can degrade proteins through several pathways. One of the most important amongst these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. A series of enzymes carry out the ubiquitination of the target proteins - E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...